Circius Pharma ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 4.8% 1.5% 3.9%  
Credit score (0-100)  0 0 43 76 49  
Credit rating  N/A N/A BBB A BBB  
Credit limit (kDKK)  0.0 0.0 0.0 32.4 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 -872 2,766 2,770  
EBITDA  0.0 0.0 -1,103 679 753  
EBIT  0.0 0.0 -1,335 -15.0 -2,183  
Pre-tax profit (PTP)  0.0 0.0 -1,342.8 -15.9 -2,242.5  
Net earnings  0.0 0.0 -1,342.8 -15.9 -2,242.5  
Pre-tax profit without non-rec. items  0.0 0.0 -1,343 -15.9 -2,242  

 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 0.0 5,696 5,680 3,437  
Interest-bearing liabilities  0.0 0.0 2,618 3,184 1,906  
Balance sheet total (assets)  0.0 0.0 9,658 9,797 6,659  

Net Debt  0.0 0.0 2,488 3,003 1,243  
 
See the entire balance sheet

Volume 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 -872 2,766 2,770  
Gross profit growth  0.0% 0.0% 0.0% 0.0% 0.2%  
Employees  0 0 1 2 2  
Employee growth %  0.0% 0.0% 0.0% 100.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 9,658 9,797 6,659  
Balance sheet change%  0.0% 0.0% 0.0% 1.4% -32.0%  
Added value  0.0 0.0 -1,103.5 216.3 752.9  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 6,476 -1,388 -5,873  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 -1.0 -2.0 -3.0  

Profitability 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 153.1% -0.5% -78.8%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% -13.8% 0.4% -26.5%  
ROI %  0.0% 0.0% -16.1% 0.5% -30.7%  
ROE %  0.0% 0.0% -23.6% -0.3% -49.2%  

Solidity 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 0.0% 59.0% 58.0% 51.6%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% -225.5% 442.4% 165.0%  
Gearing %  0.0% 0.0% 46.0% 56.1% 55.4%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.6% 1.9% 2.4%  

Liquidity 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.0 1.2 4.0 2.7  
Current Ratio  0.0 0.0 1.2 4.0 2.7  
Cash and cash equivalent  0.0 0.0 130.5 181.0 663.1  

Capital use efficiency 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 541.5 2,808.4 2,222.7  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 -1,103 108 376  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 -1,103 339 376  
EBIT / employee  0 0 -1,335 -8 -1,092  
Net earnings / employee  0 0 -1,343 -8 -1,121